Jeevan Scientific Technology Ltd: Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Changing Market Perception

Jeevan Scientific Technology Ltd, a micro-cap player in the Healthcare Services sector, currently trades at ₹78.60, slightly down 1.37% from its previous close of ₹79.69. The stock’s 52-week range spans from ₹32.85 to ₹93.90, indicating significant volatility over the past year. Despite this, the company’s valuation grade has improved from 'fair' to 'attractive' as of the latest assessment, a shift that merits close examination.

The most striking change is observed in the price-to-earnings (P/E) ratio, which stands at an anomalous -959.97. This negative figure is indicative of losses or accounting peculiarities, making traditional P/E comparisons less meaningful. However, the price-to-book value (P/BV) ratio at 2.14 offers a more tangible valuation anchor, suggesting the stock is trading at just over twice its book value. This P/BV level is relatively moderate within the healthcare services micro-cap universe, where peers often command higher multiples.

Enterprise value to EBITDA (EV/EBITDA) is another critical metric, with Jeevan Scientific Technology Ltd at 16.82. While this is higher than some peers like Venus Remedies (16.26) and Fredun Pharma (16.38), it remains below the very expensive valuations of companies such as Shukra Pharma (47.3) and Bliss GVS Pharma (28.42). This positions Jeevan Scientific Technology as reasonably valued on an operational earnings basis.

Comparative Valuation: Peers and Sector Context

When benchmarked against its healthcare services peers, Jeevan Scientific Technology Ltd’s valuation appears more attractive. Several competitors are classified as 'very expensive' with P/E ratios ranging from 30.75 (Jagsonpal Pharma) to 51.8 (Shukra Pharma), and EV/EBITDA multiples well above 20. This disparity highlights the relative value proposition of Jeevan Scientific Technology, especially for investors seeking exposure to the healthcare services sector without paying a premium.

Notably, Fredun Pharma is rated 'attractive' with a P/E of 37.27 and EV/EBITDA of 16.38, close to Jeevan Scientific’s operational multiples but at a higher price level. Meanwhile, Syncom Formulations is rated 'fair' with a P/E of 17.63 and EV/EBITDA of 15.96, indicating a more balanced valuation stance. The presence of 'risky' and 'very expensive' grades among peers underscores the fragmented nature of valuations within this sector segment.

Financial Performance and Quality Metrics

Jeevan Scientific Technology’s return on capital employed (ROCE) stands at 3.81%, while return on equity (ROE) is slightly negative at -0.22%. These figures suggest modest operational efficiency and challenges in generating shareholder returns, which partly explain the cautious market valuation. The absence of dividend yield further limits income-oriented appeal.

Despite these headwinds, the stock has delivered impressive price returns over certain periods. Year-to-date (YTD) returns are 21.94%, significantly outperforming the Sensex’s negative 9.87% over the same timeframe. Over one year, the stock has surged 108.16%, contrasting with the Sensex’s 6.10% decline. Even over three years, Jeevan Scientific Technology has outpaced the benchmark with a 68.60% gain versus Sensex’s 21.18%. However, the five-year return of -27.92% versus Sensex’s 46.30% indicates past volatility and periods of underperformance.

Price Movement and Market Sentiment

On 17 Jun 2026, the stock traded between ₹77.06 and ₹79.69, closing near the lower end of the day’s range. The slight decline of 1.37% reflects short-term profit-taking or cautious sentiment amid broader market conditions. The stock’s recent weekly return of 1.39% trails the Sensex’s 3.91%, while the monthly return of -6.33% contrasts with the Sensex’s positive 2.09%, signalling some near-term pressure despite longer-term outperformance.

Mojo Score and Rating Upgrade

MarketsMOJO assigns Jeevan Scientific Technology a Mojo Score of 61.0, reflecting a moderate investment appeal. The company’s Mojo Grade was upgraded from 'Sell' to 'Hold' on 1 Apr 2025, signalling improved confidence in the stock’s prospects. This upgrade aligns with the valuation grade improvement from 'fair' to 'attractive', suggesting that the market is beginning to recognise value despite the company’s micro-cap status and financial challenges.

Investors should note that the micro-cap classification entails higher volatility and risk, but also potential for outsized returns if operational performance and market sentiment improve further.

Investment Implications and Outlook

The shift in valuation parameters for Jeevan Scientific Technology Ltd indicates a more favourable price entry point relative to its historical and peer averages. While the negative P/E ratio warrants caution, the reasonable P/BV and EV/EBITDA multiples, combined with strong recent price returns, suggest that the stock may be undervalued by the market.

However, the company’s modest ROCE and negative ROE highlight ongoing operational challenges that investors must monitor closely. The healthcare services sector remains competitive, and Jeevan Scientific Technology’s ability to sustain growth and improve profitability will be critical to justify its upgraded valuation.

Given the mixed signals, a 'Hold' rating appears appropriate, reflecting balanced risk and reward. Investors seeking exposure to healthcare micro-caps may consider Jeevan Scientific Technology as part of a diversified portfolio, while remaining vigilant on quarterly performance and sector developments.

Conclusion

Jeevan Scientific Technology Ltd’s recent valuation upgrade from fair to attractive, coupled with a Mojo Grade improvement to Hold, marks a significant development for this healthcare services micro-cap. The stock’s relative valuation against peers and its strong price returns over the past year provide a compelling case for renewed investor interest. Nonetheless, financial metrics such as ROCE and ROE suggest that operational improvements are necessary to sustain this momentum. As such, the stock presents a cautiously optimistic opportunity for investors willing to navigate micro-cap volatility within the healthcare sector.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today